Oncology

Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.

The company announced Phase II data and plans for its registrational Phase III trial as CEO Mark Erlander and chief financial officer James Levine left the company.

The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.

Zydus is to gain from a world-first nod for a Menkes disease drug in the US amid speculation on a deal to acquire Ardelyx. Scrip examines how Zycubo approval, Agenus’s oncology BOT/BAL combination progress and a Formycon partnership help the Indian major

Enhertu's approval for ever-lower levels of HER2 expression is pushing standard immunohistochemistry assays beyond their limits. Pathologists say they have a solution.

In a presentation at the J.P. Morgan Healthcare Conference and an interview with Scrip, CEO Amy Burroughs laid out Terns’ plans for its allosteric BCR-ABL inhibitor in CML.

Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.

Cambridge, MA-based company seeks to create two-sided marketplace connecting care delivery insights with biopharma drug development.

Privately held Dark Blue’s lead candidate is for acute myeloid leukemia, but the British biotech is also developing small-molecule inhibitors for solid tumors.

Deal Snapshot: The Paris-headquartered group is the latest drugmaker to link up with the artificial intelligence-driven specialist which has recently listed in Hong Kong.

A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?

The FDA approved the PARP inhibitor for metastatic castration-resistant prostate cancer before chemotherapy.